Literature DB >> 21226639

Biologic properties and clinical uses of rifaximin.

Herbert L DuPont1.   

Abstract

INTRODUCTION: Rifaximin is increasingly being used to treat acute and chronic gastrointestinal infections and disorders. The drug exerts its beneficial effect through a variety of gut-selective mechanisms involving the host intestinal microbiota. AREAS COVERED: Abstracts of all publications listed in PubMed on the topic of rifaximin are reviewed to determine their potential value in the understanding of mechanisms of rifaximin activity. The author's extensive file on the drug is also used in the review. EXPERT OPINION: Rifaximin inhibits a broad spectrum of bacteria in the bile-rich small bowel and susceptible bacteria in the aqueous colon, and alters microbial virulence and epithelial cell function. The different mechanisms of action of rifaximin potentially explain the use of the drug in widely varied diseases and syndromes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21226639     DOI: 10.1517/14656566.2011.546347

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  15 in total

Review 1.  Gut microbiome and liver disease.

Authors:  Naga S Betrapally; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Transl Res       Date:  2016-07-15       Impact factor: 7.012

2.  Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.

Authors:  Qiang Zhu; Li Zou; Kumaravelu Jagavelu; Douglas A Simonetto; Robert C Huebert; Zhi-Dong Jiang; Herbert L DuPont; Vijay H Shah
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

3.  Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids.

Authors:  Jie Jian; Mei-Tong Nie; Baoyu Xiang; Hui Qian; Chuan Yin; Xin Zhang; Menghui Zhang; Xuan Zhu; Wei-Fen Xie
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

4.  High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.

Authors:  Puneeta Tandon; Angela Delisle; Jeffrey E Topal; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-17       Impact factor: 11.382

Review 5.  Use of rifaximin in gastrointestinal and liver diseases.

Authors:  Rani H Shayto; Rachel Abou Mrad; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 6.  Novel prevention strategies for bacterial infections in cirrhosis.

Authors:  Kathleen Yan; Guadalupe Garcia-Tsao
Journal:  Expert Opin Pharmacother       Date:  2016-02-23       Impact factor: 3.889

7.  Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.

Authors:  Vishesh Kothary; Ellen J Scherl; Brian Bosworth; Zhi-Dong Jiang; Herbert L Dupont; Josee Harel; Kenneth W Simpson; Belgin Dogan
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

8.  Effects of Rifaximin on Central Responses to Social Stress-a Pilot Experiment.

Authors:  Huiying Wang; Christoph Braun; Paul Enck
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 9.  Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review.

Authors:  Huiying Wang; In-Seon Lee; Christoph Braun; Paul Enck
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

10.  Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis.

Authors:  Caroline Schrodt; Erin E McHugh; Mary Ann Gawinowicz; Herbert L Dupont; Eric L Brown
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.